WST West Pharmaceutical Services (WST) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0000105770
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
454
13F, latest reported quarter
Conversions, 180 days
10
Codes C/M, not in net · $1.4M priced
What the filings say about WST
Insiders, 180 days
-$5.4M net sold
1 seller · 50% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-07-22
West Pharmaceutical Services insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, WEST PHARMACEUTICAL SERVICES INC insiders sold a net $5.4M of stock across 86 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Sep 14, 2026.
- The trade is 11.6% of the 21,817 shares held after it.
- No other insider sold within 30 days.
- 454 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Sr. VP & Chief HR Officer Favorite Annette F sold about $921.3K of WST under a 10b5-1 plan on Sep 15, 2026; 454 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Sep 11, 2026.
- The trade is 11.5% of the 21,817 shares held after it.
- No other insider sold within 30 days.
- 454 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Sr. VP & Chief HR Officer Favorite Annette F sold about $887.5K of WST under a 10b5-1 plan on Sep 14, 2026; 454 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Sep 8, 2026.
- The trade is 11.5% of the 21,817 shares held after it.
- No other insider sold within 30 days.
- 454 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Sr. VP & Chief HR Officer Favorite Annette F sold about $862.5K of WST under a 10b5-1 plan on Sep 11, 2026; 454 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Apr 27, 2026.
- The trade is 16.7% of the 16,844 shares held after it.
- No other insider sold within 30 days.
- 454 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Sr. VP & Chief HR Officer Favorite Annette F sold about $960.1K of WST on Sep 8, 2026, the largest insider sale at the company since 2024; 454 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Apr 27, 2026.
- The trade is 16.7% of the 16,844 shares held after it.
- No other insider sold within 30 days.
- 454 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Sr. VP & Chief HR Officer Favorite Annette F sold about $960.4K of WST on Sep 8, 2026, the largest insider sale at the company since 2024; 454 funds added in the latest 13F quarter.86 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$5.4M over 180 days
-$5.4M over 90 days
below 78% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
454 funds bought in last quarter
more than 94% of Medical Devices
Revenue
+6.3% year over year
below 61% of Medical Devices
Margin
16.1% net margin
more than 89% of Medical Devices
Buybacks
$454.3M repurchased, FY to 2026-06-30
more than 86% of Medical Devices
Short interest
2.9% of the float short (float per yahoo 2026-10-27) · 4.2 days to cover · settled 2026-10-15
below 54% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch WST
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+30.0%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns WST: institutional holders (13F)
13F holdings, latest reported quarter
6,651,784 sh
$2.4B
4,613,134 sh
$1.7B
4,015,766 sh
$1.4B
3,574,816 sh
$1.3B
3,348,698 sh
$1.2B
Congress trades in WST
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-07-22 · disclosed 22 days later
$1,001 - $15,000
Bought 2025-06-17 · disclosed 57 days later
$1,001 - $15,000
Sold 2025-04-08 · disclosed 30 days later
$1,001 - $15,000
Bought 2025-02-25 · disclosed 30 days later
$1,001 - $15,000
Sold 2025-02-13 · disclosed 21 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
WST planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
WST mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus KAR Health Sciences Fund
$5.4M position · as of 2026-06-30
5.9%
Virtus KAR Mid-Cap Core Fund
$93.6M position · as of 2026-06-30
5.3%
Virtus KAR Mid-Cap ETF
$2.2M position · as of 2026-07-31
4.9%
Virtus KAR Mid-Cap Growth Fund
$19.4M position · as of 2026-06-30
4.8%
Motley Fool Mid-Cap Growth ETF
$5.5M position · as of 2026-05-31
4.7%
BBH Select Mid Cap ETF
$19.3M position · as of 2026-07-31
4.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$7.2M
$4.1M
$3.8M
-41%
+18%
2024
$8.4M
$5.3M
$1.8M
-30%
+3%
2023
$9.4M
$17.0M
$2.1M
-25%
+0%
2022
$7.9M
-$12.1M
$1.8M
-50%
-2%
2021
$9.5M
$35.1M
$2.0M
+0%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $5.4M sold by insiders over 180 days, 454 funds added last quarter. Each figure is a federal filing, dated the day it went public.
WST financials
Revenue growth
+6.3%
XBRL, annual
Net margin
16.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.3B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM WST
| FY Dec 2025 | $3.1B |
| FY Dec 2024 | $2.9B |
| FY Dec 2023 | $2.9B |
| FY Dec 2022 | $2.9B |
| FY Dec 2021 | $2.8B |
| Jun 2026 | $872.3M |
| Mar 2026 | $844.9M |
| Dec 2025 | $805.0M |
| Sep 2025 | $804.6M |
| Jun 2025 | $766.5M |
| Mar 2025 | $698.0M |
| Dec 2024 | $748.8M |
| Sep 2024 | $746.9M |
At each fiscal year end
Single quarter
Net margin, TTM
+17.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM WST
| FY Dec 2025 | +16.1% |
| FY Dec 2024 | +17.0% |
| FY Dec 2023 | +20.1% |
| FY Dec 2022 | +20.3% |
| FY Dec 2021 | +23.4% |
| Jun 2026 | +17.7% |
| Mar 2026 | +16.4% |
| Dec 2025 | +16.4% |
| Sep 2025 | +17.4% |
| Jun 2025 | +17.2% |
| Mar 2025 | +12.9% |
| Dec 2024 | +17.4% |
| Sep 2024 | +18.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$436.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM WST
| FY Dec 2025 | $468.9M |
| FY Dec 2024 | $276.4M |
| FY Dec 2023 | $414.5M |
| FY Dec 2022 | $439.4M |
| FY Dec 2021 | $330.6M |
| Jun 2026 | $80.8M |
| Mar 2026 | $47.2M |
| Dec 2025 | $175.0M |
| Sep 2025 | $133.9M |
| Jun 2025 | $101.9M |
| Mar 2025 | $58.1M |
| Dec 2024 | $85.2M |
| Sep 2024 | $98.8M |
At each fiscal year end
Single quarter
Debt to equity
0.07x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity WST
| FY Dec 2025 | 0.06x |
| FY Dec 2024 | 0.08x |
| FY Dec 2023 | 0.07x |
| FY Dec 2022 | 0.08x |
| FY Dec 2021 | 0.11x |
| Jun 2026 | 0.07x |
| Mar 2026 | 0.07x |
| Dec 2025 | 0.06x |
| Sep 2025 | 0.07x |
| Jun 2025 | 0.07x |
| Mar 2025 | 0.08x |
| Dec 2024 | 0.08x |
| Sep 2024 | 0.07x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
3.26x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt WST
| FY Dec 2025 | 3.72x |
| FY Dec 2024 | 3.23x |
| FY Dec 2023 | 3.75x |
| FY Dec 2022 | 3.47x |
| FY Dec 2021 | 2.31x |
| Jun 2026 | 3.26x |
| Mar 2026 | 3.53x |
| Dec 2025 | 3.72x |
| Sep 2025 | 3.42x |
| Jun 2025 | 3.34x |
| Mar 2025 | 3.28x |
| Dec 2024 | 3.23x |
| Sep 2024 | 3.47x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+19.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity WST
| FY Dec 2025 | +16.9% |
| FY Dec 2024 | +17.7% |
| FY Dec 2023 | +21.3% |
| FY Dec 2022 | +23.3% |
| FY Dec 2021 | +31.6% |
| Jun 2026 | +19.1% |
| Mar 2026 | +19.1% |
| Dec 2025 | +16.9% |
| Sep 2025 | +16.9% |
| Jun 2025 | +17.7% |
| Mar 2025 | +17.4% |
| Dec 2024 | +17.7% |
| Sep 2024 | +17.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+14.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets WST
| FY Dec 2025 | +12.5% |
| FY Dec 2024 | +13.2% |
| FY Dec 2023 | +15.9% |
| FY Dec 2022 | +16.9% |
| FY Dec 2021 | +21.7% |
| Jun 2026 | +14.1% |
| Mar 2026 | +14.0% |
| Dec 2025 | +12.5% |
| Sep 2025 | +12.6% |
| Jun 2025 | +13.1% |
| Mar 2025 | +12.9% |
| Dec 2024 | +13.2% |
| Sep 2024 | +13.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+20.0%
operating income after a 20.8% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital WST
| FY Dec 2025 | +18.7% |
| FY Dec 2024 | +20.1% |
| FY Dec 2023 | +26.4% |
| FY Dec 2022 | +32.3% |
| FY Dec 2021 | +38.9% |
| Jun 2026 | +20.0% |
| Mar 2026 | +20.0% |
| Dec 2025 | +18.7% |
| Sep 2025 | +18.3% |
| Jun 2025 | +18.6% |
| Mar 2025 | +18.6% |
| Dec 2024 | +20.1% |
| Sep 2024 | +20.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+20.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed WST
| FY Dec 2025 | +17.4% |
| FY Dec 2024 | +18.2% |
| FY Dec 2023 | +21.6% |
| FY Dec 2022 | +25.2% |
| FY Dec 2021 | +30.0% |
| Jun 2026 | +20.1% |
| Mar 2026 | +20.1% |
| Dec 2025 | +17.4% |
| Sep 2025 | +17.7% |
| Jun 2025 | +18.7% |
| Mar 2025 | +18.3% |
| Dec 2024 | +18.2% |
| Sep 2024 | +17.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
51.00x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing WST
| FY Dec 2025 | 40.52x |
| FY Dec 2024 | 48.96x |
| FY Dec 2023 | 44.69x |
| FY Dec 2022 | 30.45x |
| FY Dec 2021 | 54.16x |
| Jun 2026 | 45.97x |
| Mar 2026 | 33.51x |
| Dec 2025 | 40.52x |
| Sep 2025 | 38.86x |
| Jun 2025 | 32.75x |
| Mar 2025 | 35.15x |
| Dec 2024 | 48.96x |
| Sep 2024 | 44.53x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$27.8B
market value at close 2026-10-27 on 2026-07-20 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value WST
| FY Dec 2025 | $19.2B |
| FY Dec 2024 | $23.4B |
| FY Dec 2023 | $25.4B |
| FY Dec 2022 | $16.7B |
| FY Dec 2021 | $34.2B |
| Jun 2026 | $25.1B |
| Mar 2026 | $17.7B |
| Dec 2025 | $19.2B |
| Sep 2025 | $18.4B |
| Jun 2025 | $15.4B |
| Mar 2025 | $16.0B |
| Dec 2024 | $23.4B |
| Sep 2024 | $21.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+1.6%
TTM free cash flow over market value at close 2026-10-27
FCF yield WST
| FY Dec 2025 | +2.4% |
| FY Dec 2024 | +1.2% |
| FY Dec 2023 | +1.6% |
| FY Dec 2022 | +2.5% |
| FY Dec 2021 | +1.0% |
| Jun 2026 | +1.7% |
| Mar 2026 | +2.5% |
| Dec 2025 | +2.4% |
| Sep 2025 | +2.0% |
| Jun 2025 | +2.2% |
| Mar 2025 | +1.9% |
| Dec 2024 | +1.2% |
| Sep 2024 | +1.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
3.01x
P/E over trailing EPS growth of 17%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing WST
| FY Dec 2025 | 27.11x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 23.03x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.61x |
| Jun 2026 | 2.72x |
| Mar 2026 | 1.92x |
| Dec 2025 | 27.11x |
| Sep 2025 | 261.94x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $3.1B | $2.9B | $2.9B | $2.9B |
| Gross profit | $1.1B | $998.5M | $1.1B | $1.1B |
| Operating income | $584.9M | $569.9M | $676.0M | $734.0M |
| Net income | $493.7M | $492.7M | $593.4M | $585.9M |
| EPS (diluted) | 6.79 | 6.69 | 7.88 | 7.73 |
| Operating cash flow | $754.8M | $653.4M | $776.5M | $724.0M |
| Cash | $791.3M | $484.6M | $853.9M | $894.3M |
| Long-term debt | $202.8M | $202.6M | $72.8M | $206.7M |
| Buybacks | $134.0M | $560.9M | $438.3M | $202.8M |
| Dividends paid | $61.2M | $59.1M | $57.0M | $54.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
WST Stock Sonar score 6/7 axes
Find similar shapesCompareWST ranks highest on profitability (89th percentile) and financial health (84th), and lowest on insider conviction (13th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
WST filings, in plain words
Are West Pharmaceutical Services insiders buying or selling WST?
In the 180 days to 2026-10-28, West Pharmaceutical Services insiders were net sellers, a net $5.4M across purchases and sales reported on Form 4, by 1 seller.
Have members of Congress traded WST?
Yes, but not in the year to 2026-10-28; the latest on record is a sale by Lisa McClain dated 2025-07-22.
Read the full summary
In the 180 days to 2026-10-28, West Pharmaceutical Services insiders were net sellers of WST, a net $5.4M across purchases and sales reported on Form 4 by 1 seller. 50% of the 6 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Members of Congress have disclosed trades in WST, none in the last year; the latest on record is a sale by Lisa McClain dated 2025-07-22. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
